

Supplementary Material

Title: Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease

Authors: Estrella Morenas-Rodríguez, M.D.^{1,2,3}, Daniel Alcolea M.D., Ph.D.^{1,2,3}, Marc Suárez-Calvet M.D, Ph.D.^{4,5}, Laia Muñoz-Llahuna BSc^{1,2,3}, Eduard Vilaplana Ph.D.^{1,2,3}, Isabel Sala Matavera Ph.D.^{1,2,3}, Andrea Subirana MSc^{1,2,3}, Marta Querol-Vilaseca MSc.^{1,2,3}, María Carmona-Iragui M.D., Ph.D.^{1,2,3}, Ignacio Illán-Gala M.D.^{1,2,3}, Roser Ribosa-Nogué M.D.^{1,2,3}, Rafael Blesa M.D., Ph.D.^{1,2,3}, Christian Haass, PhD^{4,5,6}, Juan Fortea M.D., Ph.D.^{1,2,3}, Alberto Lleó, M.D., Ph.D.*^{1,2,3}.


Affiliations

¹ Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, ² Institut d'Investigacions Biomediques Sant Pau – Universitat Autònoma de Barcelona, ³ Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III. ⁴ Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany. ⁵ German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. ⁶ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Suppl. table S1. Demographic and basic clinical data from DLB patients


	DLB with AD copathology (n = 20)	DLB without AD copathology (n = 17)	p-value
Age, y ± SD	77.1 ± 1.1	75.7 ± 1.2	0.420
Sex, Females % (n)	55% (11)	52.9% (9)	1
MMSE, mean ± SD	21.9 ± 1.2	24.2 ± 0.8	0.165
Mean follow-up time (y) ± SD	2.2 ± 0.5	2.6 ± 0.6	0.568
APOEε4, %* (n)	30% (6)	17.6% (3)	0.462

Supplementary figure S1. Relationship between glial biomarkers by diagnosis



CN: cognitively normal controls, DLB: Dementia with Lewy Bodies, prodDLB: prodromal DLB, AD: Alzheimer's disease, prodAD: prodromal AD.

Supplementary figure S2. Relationship between glial and core AD biomarkers



CN: cognitively normal controls, DLB: Dementia with Lewy Bodies, prodDLB: prodromal DLB,

Supplementary methods

Supplementary table S2. Intra and inter-assay CV% per measured protein.

Assay	intra-assay CV%*	inter-assay CV%**
Aβ1-42	2.01%	11.07%
t-tau	2.01%	10.89%
p-tau	1.77%	17.24%
sTREM2	3.9%	13.02%
YKL-40	4.03%	6.3%
PGRN	4.47%	10.7%

* Intra-assay CV% was calculated as the mean of all CV% from the samples included per assay

** We included the following internal controls per assay to calculate the inter-assay CV%. Internal controls are samples with an already known concentration that we included in all the assays. In Braquets there is the mean from all assays and the interplate CV % of each internal control. Aβ1-42: L10-001 (mean: 392.5 pg/mL, CV%: 10.85%), Aβ384 (mean: 359 pg/mL, CV%: 12.48%), Aβ500 (mean: 472.73 pg/mL, CV%: 9.87%). t-tau: tau300 (mean: 297.78 pg/mL, CV%: 10.89%). p-tau: pTau125 (mean: 132.98 pg/mL, CV%: 17.24%). sTREM2: Interplate D (mean: 3.08 ng/mL, CV%: 11.54%) and Interplate

E (mean: 4.44 ng/mL, CV%: 14.51%). YKL-40: YKL40H (mean: 142.84 ng/mL, CV%: 6.3%). PGRN: L10-84 (mean: 3.67 ng/mL, CV%: 15.45%) and L15-033 (mean: 5.12 ng/mL, CV%: 5.12%)

Standard curve calculation per assay

- Standard curves for Innostest assays ($A\beta_{1-42}$, t-tau and p-tau) were calculated with a 4-parameter logistic regression (provided by the manufacturer).

- Standard curves for sTREM2 assays were calculated by with a 4-parameter logistic regression in the MSD software.

- Standard curves for YKL-40 assays were calculated by a polinomic regression in Excel as recommended by the manufacturer.

- Standard curves for PGRN assays were calculated by a polinomic regression in Excel as recommended by the manufacturer.

All the assays had standard curves with a R squared over 0.95